Back to top
more

The Cooper Companies (COO)

(Real Time Quote from BATS)

$93.55 USD

93.55
776,707

+0.94 (1.02%)

Updated Jul 31, 2024 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.

Will HSA Member Growth Aid HealthEquity's (HQY) Q3 Earnings?

by Zacks Equity Research

HealthEquity's (HQY) top line is likely to be driven by solid Health Savings Accounts (HSA) member growth in the fiscal third quarter. However, cutthroat competition in the niche space is concerning.

Can Segmental Growth Boost Veeva Systems' (VEEV) Q3 Earnings?

by Zacks Equity Research

Veeva Systems (VEEV) likely to gain from solid segmental show in fiscal Q3; competition stiff.

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal Q2 earnings likely to be marred by a soft Dental unit; Animal Health looks promising.

Why Is Cooper Cos. (COO) Up 5.1% Since Last Earnings Report?

by Zacks Equity Research

Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Cooper's MiSight Lens Effective in Checking Juvenile Myopia

    by Zacks Equity Research

    Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.

      Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3

      by Zacks Equity Research

      Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.

        Cooper Cos. (COO) Q3 Earn Earnings ings Lag Estimates

        by Zacks Equity Research

        Cooper Cos. (COO) delivered earnings and revenue surprises of -2.60% and 1.00%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?

          Cooper Cos. (COO) Q3 Earnings Preview: What's Shaping Up?

          by Zacks Equity Research

          Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

            What's in Store for Cooper Companies' (COO) Q3 Earnings?

            by Zacks Equity Research

            Cooper Companies (COO) is likely to gain from strong segmental show in Q3; a competitive industry raises concern.

              Will Medtronic (MDT) Q1 Earnings Show Overall Progress?

              by Zacks Equity Research

              In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.

                Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

                by Zacks Equity Research

                Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.

                  CVS Health's PBM Selling Season Strong, Aetna Deal on Track

                  by Zacks Equity Research

                  A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.

                    Amedisys (AMED) Grows on Robust Home Health, Personal Care

                    by Zacks Equity Research

                    Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.

                      Can Cooper Cos. (COO) Keep the Earnings Surprise Streak Alive?

                      by Zacks Equity Research

                      Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                        Integra LifeSciences Codman Arm Strong, Competition Rife

                        by Zacks Equity Research

                        Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.

                          Inogen's Solid Europe Business Shapes Q2, Prospects Bright

                          by Zacks Equity Research

                          Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.

                            Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid

                            by Zacks Equity Research

                            Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.

                              Boston Scientific to Expand Within PI Via VENITI Buyout

                              by Zacks Equity Research

                              Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.

                                Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now

                                by Zacks Equity Research

                                DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.

                                  Here's Why You Should Hold on to Ecolab (ECL) Stock Now

                                  by Zacks Equity Research

                                  Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.

                                    Varian Acquires humediQ, Boosts Motion Management Portfolio

                                    by Zacks Equity Research

                                    Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.

                                      COO or MMSI: Which Is the Better Value Stock Right Now?

                                      by Zacks Equity Research

                                      COO vs. MMSI: Which Stock Is the Better Value Option?

                                        What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?

                                        by Zacks Equity Research

                                        Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.

                                          Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?

                                          by Zacks Equity Research

                                          DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.

                                            Why Cardinal Health (CAH) Could Be Positioned for a Slump

                                            by Zacks Equity Research

                                            Cardinal Health (CAH) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.